ARTICLE | Company News

Novartis sales and marketing update

October 19, 2015 7:00 AM UTC

The German Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that Zykadia ceritinib from Novartis had “no hint of added benefit” in patients with non-small cell lung cancer (NSCLC). The agency said the company did not provide suitable data, including direct-comparison studies with chemotherapy, and the unadjusted historical comparison data provided were “not evaluable.” ...